Findings

What do systematic reviews say?

13 questions · 13 findings · 1 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 23.1%Low 8 · 61.5%Moderate 2 · 15.4%High 0 · 0%

Cannabinoids vs placebo

Absence of nausea ( · people with chemotherapy‐induced nausea and vomiting

Cannabinoids showed no clear difference in absence of nausea ( compared with placebo (low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 2 [0.2, 21]
2 studies · 96 participants
Low

Cannabinoids vs other anti‐emetic agent

Participant preference · people with chemotherapy‐induced nausea and vomiting

Cannabinoids may leads to higher participant preference ( compared with other anti‐emetic agent (low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 2.8 [1.9, 4]
9 studies · 799 participants
Low

Cannabinoids vs other anti‐emetic agent

Withdrawal for any reason (medium term: treatment duration from 5 to 8 weeks) · people with chemotherapy‐induced nausea and vomiting

Cannabinoids may leads to higher withdrawal any reason ( compared with other anti‐emetic agent (low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 3.5 [1.4, 9]
1 study · 42 participants
Low

Cannabinoids vs other anti‐emetic agent

Lack of efficacy withdrawal · people with chemotherapy‐induced nausea and vomiting

It is very uncertain whether cannabinoids changes withdrawal due to lack of efficacy ( compared with other anti‐emetic agent (very low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 0.97 [0.04, 21]
2 studies · 118 participants
Very low

Cannabinoids vs other anti‐emetic agent

Withdrawals due to adverse events · people with chemotherapy‐induced nausea and vomiting

Cannabinoids may leads to higher withdrawal due to adverse event ( compared with other anti‐emetic agent (low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 3.2 [1.3, 8]
6 studies · 740 participants
Low

Cannabinoids vs placebo

Absence of vomiting ( · people with chemotherapy‐induced nausea and vomiting

Cannabinoids may leads to higher absence of vomiting ( compared with placebo (low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 5.7 [2.6, 12.6]
3 studies · 168 participants
Low

Cannabinoids vs placebo

Absence of nausea and vomiting ( · people with chemotherapy‐induced nausea and vomiting

Cannabinoids probably leads to higher absence of nausea and vomiting ( compared with placebo (moderate certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 2.9 [1.8, 4.7]
3 studies · 288 participants
Moderate

Cannabinoids vs placebo

Participant preference · people with chemotherapy‐induced nausea and vomiting

Cannabinoids may leads to higher participant preference ( compared with placebo (low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 4.8 [1.7, 13]
2 studies · 256 participants
Low

Cannabinoids vs placebo

Withdrawal for any reason (medium term: treatment duration from 5 to 8 weeks) · people with chemotherapy‐induced nausea and vomiting

It is very uncertain whether cannabinoids changes withdrawal any reason ( compared with placebo (very low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 0.31 [0.01, 7]
1 study · 33 participants
Very low

Cannabinoids vs placebo

Withdrawals due to adverse events · people with chemotherapy‐induced nausea and vomiting

It is very uncertain whether cannabinoids changes withdrawal due to adverse event ( compared with placebo (very low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 6.9 [1.96, 24]
2 studies · 276 participants
Very low

Cannabinoids vs other anti‐emetic agent

Absence of nausea ( · people with chemotherapy‐induced nausea and vomiting

Cannabinoids showed no clear difference in absence of nausea ( compared with other anti‐emetic agent (low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 1.46 [0.67, 3.15]
5 studies · 258 participants
Low

Cannabinoids vs other anti‐emetic agent

Absence of vomiting ( · people with chemotherapy‐induced nausea and vomiting

Cannabinoids showed no clear difference in absence of vomiting ( compared with other anti‐emetic agent (moderate certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 1.1 [0.86, 1.4]
4 studies · 209 participants
Moderate

Cannabinoids vs other anti‐emetic agent

Absence of nausea and vomiting ( · people with chemotherapy‐induced nausea and vomiting

Cannabinoids showed no clear difference in absence of nausea and vomiting ( compared with other anti‐emetic agent (low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 2 [0.74, 5.4]
4 studies · 414 participants
Low